Lansoprazole is a drug owned by Dexcel Pharma Technologies Ltd. It is protected by 2 US drug patents filed from 2021 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 21, 2036. Details of Lansoprazole's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11077055 | Orally disintegrating compositions |
Apr, 2036
(11 years from now) | Active |
| US11986554 | Orally disintegrating compositions |
Apr, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lansoprazole's patents.
Latest Legal Activities on Lansoprazole's Patents
Given below is the list of recent legal activities going on the following patents of Lansoprazole.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 03 Aug, 2021 | US11077055 |
| Recordation of Patent Grant Mailed Critical | 03 Aug, 2021 | US11077055 |
| Email Notification Critical | 15 Jul, 2021 | US11077055 |
| Issue Notification Mailed Critical | 14 Jul, 2021 | US11077055 |
| Dispatch to FDC | 28 Jun, 2021 | US11077055 |
| Application Is Considered Ready for Issue Critical | 28 Jun, 2021 | US11077055 |
| Issue Fee Payment Verified Critical | 23 Jun, 2021 | US11077055 |
| Issue Fee Payment Received Critical | 23 Jun, 2021 | US11077055 |
| Electronic Review Critical | 19 Jun, 2021 | US11077055 |
| Email Notification Critical | 18 Jun, 2021 | US11077055 |
US patents provide insights into the exclusivity only within the United States, but Lansoprazole is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lansoprazole's family patents as well as insights into ongoing legal events on those patents.
Lansoprazole's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lansoprazole's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 21, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lansoprazole Generic API suppliers:
Lansoprazole is the generic name for the brand Lansoprazole. 27 different companies have already filed for the generic of Lansoprazole, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lansoprazole's generic
Alternative Brands for Lansoprazole
There are several other brand drugs using the same active ingredient (Lansoprazole) as Lansoprazole. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Takeda Pharms Na |
| |||
| Takeda Pharms Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Lansoprazole, Lansoprazole's active ingredient. Check the complete list of approved generic manufacturers for Lansoprazole
About Lansoprazole
Lansoprazole is a drug owned by Dexcel Pharma Technologies Ltd. Lansoprazole uses Lansoprazole as an active ingredient. Lansoprazole was launched by Dexcel in 2016.
Approval Date:
Lansoprazole was approved by FDA for market use on 07 June, 2016.
Active Ingredient:
Lansoprazole uses Lansoprazole as the active ingredient. Check out other Drugs and Companies using Lansoprazole ingredient
Dosage:
Lansoprazole is available in tablet, orally disintegrating, delayed release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 15MG | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | Over the counter | ORAL |